


**Product Name** : ATUX-1215  
**Cat. No.** : PC-21366  
**CAS No.** : 2910930-01-5  
**Molecular Formula** : C<sub>27</sub>H<sub>24</sub>F<sub>5</sub>NO<sub>4</sub>S  
**Molecular Weight** : 553.54  
**Target** : Protein Phosphatase/PTP  
**Solubility** : 10 mM in DMSO



CAS: 2910930-01-5

### Biological Activity

ATUX-1215 is a direct, orally active small molecule activator of protein phosphatase 2A (**PP2A**), suppresses bleomycin-induced fibrosis in vivo.

ATUX-1215 (1 uM) induces PP2A phosphatase activity responses in fibroblasts, reduced the level of TGFβ induction of ACTA2, COL1A1, COL1A2, and FN1 gene expression in fibroblasts.

ATUX-1215 activates PP2A responses in the BLM model and elicited potentially useful therapeutic effects.

ATUX-1215 (5 mg/kg, daily, oral) reduces the BLM-induced BALF levels of IL12p70, GM-CSF, and IL-1α in C57BL/6J mice.

ATUX-1215 shows the improved metabolic stability and bioavailability of ATUX-1215 to previously described PP2A activators.

ATUX-1215 prevents BLM-induced lung physiology changes, including the preservation of normal PV loop, compliance, tissue elastance, and forced vital capacity.

### References

Meshach Pillai, et al. *ACS Pharmacol Transl Sci*. 2023 Oct 17;6(11):1659-1672.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com